The One Lipid Marker Linked to Longevity
In a Nutshell
High cholesterol like LDL and ApoB doesn't necessarily shorten lifespan, as seen in PCSK9 mutations that lower them without longevity benefits, but ApoC3—a protein that slows triglyceride clearance—stands out: genetic variants reducing ApoC3 enrich in centenarians, cut cardiovascular risk via lower remnant cholesterol (not LDL), and promote metabolic efficiency. Lower ApoC3 through low-carb/keto diets (up to 50% drop), fructose/sugar restriction, insulin sensitivity improvements (exercise, fasting, sleep), and omega-3s (aim for 8% omega-3 index). Targeting ApoC3 offers broader heart health and longevity gains than LDL focus alone.
These notes were generated by AI and may contain inaccuracies.
I have higher cholesterol than most doctors see in their entire careers, sometimes above 700. According to prevailing models of heart disease, I probably should be dead. But I'm thriving and my heart and blood vessels are pristine. To most doctors, I'm a walking talking paradox. Curiosities like me inspired me to go into science and medicine, get my PhD, then my MD.
Heart disease is one of the leading causes of death worldwide. Chances are you or someone close to you will be affected by it. Many have been taught lower cholesterol, especially LDL bad cholesterol, is better because LDL causes heart disease and lowering it should lead to longer life. But it doesn't.
Buried in the data is a key variable you can measure and change that most people and doctors miss, one that matters for health span and lifespan. This video provides tools to modify cholesterol metabolism that might protect your heart and add years to your life and life to your years.
It's time to rethink the story about lipids and cholesterol. Modern cardiology may be focusing the spotlight in the wrong place. ApoC3 is a small protein that plays a big role in whole body health. It is modifiable and actionable.
Chapter 1: The lower is better fallacy.
Chapter 2: Introduce ApoC3, a cholesterol-related molecule you should have heard of but bet haven't, and your doctor hasn't either.
Chapter 3: How lower ApoC3 associates with longevity and differs from other lipid and cholesterol genes.
Chapter 4: Evidence-based strategies to lower ApoC3, lifestyle tools to improve cholesterol metabolism and heart health.
References, extra information, and details in the associated newsletter link below.
For decades, cardiology's guiding principle has been lower is better: lower LDL cholesterol, lower ApoB, lowers these and you lower heart disease risk. But just having lower LDL and ApoB doesn't increase health span or lifespan per se.
Example: Mutations in PCSK9 gene (target of PCSK9 inhibitors) lead to much lower LDL cholesterol and ApoB levels, but no lifespan increase. In medicine, that's a paradox. Heart disease is a leading killer, but genetics reducing LDL and heart disease risk don't provide lifespan benefit.
It's not just underpowered studies; if so, expect at least a trend toward mortality benefit, but data shows the opposite: PCSK9 loss-of-function trends toward earlier death, more mortality.
Other cholesterol and lipid genetics show signals. If lowering LDL isn't the whole story, what's missing? ApoC3, a lesser-known player in lipid and cholesterol metabolism.
Apolipoproteins are proteins that bind to fats to form lipoproteins (lipids and proteins) that transport lipids in bloodstream. They serve as structural scaffold, enzyme regulators, regulate protein activity, and address labels guiding particles to destinations.
Many apolipoproteins: ApoA, ApoB, ApoC3 (topic of video), ApoE (involved in Alzheimer's), and more.
ApoB is primary structural protein in LDL particles, proxy for LDL particle count, boogeyman of modern cardiology (each LDL particle carries one ApoB).
Shifting to ApoC3: small protein, big role in handling fat, specifically triglycerides (fat fuel in blood). Made in liver, circulates in bloodstream, slows clearance of fat triglycerides like a metabolic brake. Prevents enzyme lipoprotein lipase from breaking down triglycerides, resulting in higher circulating triglycerides hanging around longer.
People with genetic mutations reducing or turning off ApoC3 have more efficient metabolisms, better metabolic health, lower cardiovascular risk, longer lifespan.
Study on genetic variations in lipoprotein cholesterol metabolism linked to longevity: variation in ApoC3 gene led to reduced ApoC3 protein and activity, enriched in centenarians (people 100+ years old). Centenarians 2.5 times as likely to harbor specific ApoC3 genetic variant vs. shorter-lived counterparts.
LDL cholesterol and ApoB levels virtually identical between longevity ApoC3 variant group and comparators; if anything, ApoB trended slightly higher in males with longevity variant.
Longevity ApoC3 mutation group had higher HDL and lower triglyceride to HDL ratio (markers of metabolic health, efficient lipid turnover).
Survival curve of 381 people (64 with favorable ApoC3 genotype): their curve declined much more slowly; they lived longer.
Even focusing on cardiovascular outcomes: meta-analysis of 137,895 individuals found ApoC3 loss-of-function variants led to significantly lower vascular disease risk, not due to lower LDL (dropped 4% avg.), but remnant cholesterol (marker of triglyceride-rich lipoproteins) dropped 43%. Authors conclude vascular benefits not mediated by LDL cholesterol.
Pattern across genetic mutations altering cholesterol/lipid metabolism: most provide no longevity benefits (e.g., PCSK9 loss-of-function lowers LDL, cardiovascular benefits but no lifespan benefit; trend toward more mortality). By contrast, ApoC3 loss-of-function leads to efficient lipid metabolism, improved insulin sensitivity, minimal LDL impact, plus cardiovascular and longevity benefits.
Modern cardiology focuses on LDL as primary enemy (drugs to lower it), but biology of aging, metabolism, long-term health, longevity points elsewhere. ApoC3 is underrated; lowering it could improve cardiovascular risk, health span, lifespan.
Low-carb diets powerfully reduce ApoC3; low-carb and keto. Glucose potently stimulates ApoC3 production (physiologic sense: ApoC3 suppresses lipid metabolism, so glucose prioritizes carb burning over fats by increasing ApoC3 brake). More glucose, more ApoC3.
Ketogenic diet led to 50% reduction in ApoC3 in people with obesity in 2 weeks.
Fructose is even stronger stimulus for ApoC3 than glucose: cut sugar-sweetened beverages, even tropical fruits (sorry about mangoes). Restricting overall carbs biggest bang for buck (reduces glucose, fructose, things breaking down into them).
Insulin signaling suppresses ApoC3. In insulin resistance (obesity, type 2 diabetes), ApoC3 increases. Improve insulin sensitivity to lower ApoC3: low-carb/keto diets, weight loss, exercise, fasting, good sleep.
Fatty acid balance: omega-3 fatty acids (EPA/DHA from fatty fish) reduce ApoC3. Measure omega-3 index (Omega Quant service, discount code Nick Norwitz for 10% off). Aim for 8% in red blood cells (avg. American ~5%; speaker at 16%).
Saturated fat might increase ApoC3 (controversial); rules change on low-carb/keto, but on mixed macro diet with carbs, swap saturated for mono/polyunsaturated fats, especially omega-3s.
Summary of interventions to lower ApoC3: fructose/sugar restriction, low-carb/keto diets, improve insulin sensitivity, increase omega-3 fatty acids, potentially swap saturated for mono/polyunsaturated if carb-rich diet.
Pharma note: ApoC3 target with anti-sense oligonucleotide olpasiran for high triglycerides/hypertriglyceridemia (details in newsletter).
Rethink story on lipids/cholesterol: myopic focus on LDL/ ApoB overshadows other markers. ApoC3 is key player in whole body health, aging biology, fat processing, longevity. Easily modifiable.
Keep Nick Norwitz in your library
Save the videos and channels worth coming back to, and find them again in one place.
